Clinical effectiveness of early hormone therapy combined with hyperbaric oxygen therapy in patients with sudden sensorineural hearing loss
Objective To investigate and analyze the clinical effects of early hormone therapy combined with hyperbaric oxygen therapy in patients with sudden sensorineural hearing loss(SSNHL).Methods A total of 90 patients with SSNHL,admitted to our hospital from March 2022 to January 2024,were selected and randomly divided into two groups,each with 45 patients.The control group received early hormone therapy,while the observation group received hyperbaric oxygen therapy in addition to hormone therapy.The efficacy,hearing thresholds before and after treatment,coagulation function indicators,and adverse reactions were compared between the two groups.Results The clinical total effective rate in the observation group was significantly higher than that in the control group(P＜0.05).After treatment,the hearing thresholds at 500Hz,1000Hz,and 2000Hz in the observation group were lower compared to those in the control group(P＜0.05);the PT,APTT,and TT values in the observation group were higher,and the FIB value was lower compared to those in the control group(P＜0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Early hormone therapy combined with hyperbaric oxygen therapy demonstrates significant clinical efficacy in patients with sudden sensorineural hearing loss.The treatment improves hearing thresholds and coagulation function indicators,and there are no significant adverse reactions,indicating good safety.
Sudden sensorineural hearing lossHormoneHyperbaric oxygenHearing thresholdCoagulation function indicatorsAdverse reactions
NETL
NSTL
万方数据
